We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


CollabRx Announces Adrienne Craig-Kennard as VP of Global Business Development and Strategic Alliances

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "CollabRx Announces Adrienne Craig-Kennard as VP of Global Business Development and Strategic Alliances"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

CollabRx, Inc., a leading clinical decision support company and wholly owned subsidiary of Rennova Health, Inc. has announced that Adrienne Craig-Kennard will serve as Vice President of Global Business Development and Strategic Alliances. 

Craig-Kennard, an expert in international business development with more than 15 years experience in the pharmaceutical, biotechnology, and bioinformatics industries, will lead development and strategy for CollabRx. She has acted in research and product development roles in addition to business development and COO positions in her previous work.


“Adrienne has a brilliant track record as an executive in our industry,” said Thomas Mika, CEO of CollabRx. “Her ability to work and think as a scientist as well as a businesswoman has led to global success and we could not be more thrilled to have her join our team.”

“CollabRx’s ability to deliver expert solutions in precision oncology is paramount in today’s market where physicians, laboratories, payers and providers strive to achieve standardized, evidence-based care and superior clinical outcomes,” said Adrienne Craig-Kennard. ‘My background, coupled with the opportunity to become an integral part in the advancement of oncology care are an ideal fit.”

Most recently Craig Kennard was Vice President of Global Clinical Informatics Sales for Strand Life Sciences where she led global sales of software as well as services for translational research and next generation sequencing-based clinical diagnostics.

Craig-Kennard received her Bachelor of Science in Chemistry from the University of California, Berkeley and an M.B.A. from the Grenoble Graduate School of Business in France.